For fun, below is some context that might, might, foretell our future SP potential...

I have no insights on how much we would charge per patient therapeutic treatment.  But assuming apabetalone would be needed in tens of millions of people, I would estimate that our global sales would be somehwhat in the same ballpark (if not more seeing that we have no comp) as Moderna's or Pfizer's vaccines, no?  

Anyone with insights, even speculative, on a expected pricing and market size for a therapeutic, please chime in. 

Moderna's market cap is $58 Billion USD and they only have part of the vaccine market which makes up virtually all of their sales.  It is 345 times RVX's market cap of $215M CAD.  You know I have to do the math, still knowing of course that it would take a couple of years to get to Moderna's sales level, but by then we could have many other indications too, so yes I will do the math.  Assuming fully diluted RVX at 300M shares, the same market cap as Moderna's get us a RVX share price of $247 per share.

With such promise/potential to be making billions within a year or two you would think the market would see an opportunity in RVX at a share price that may one day represent a 345-bagger!
Just sayin'

Moderna expects $18.4 billion in COVID-19 vaccine sales in 2021

https://www.reuters.com/article/us-health-coronavirus-moderna-idUSKBN2AP1JG